|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.3100 - 0.3300|
|52 Week Range||0.0680 - 0.4660|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimizationVANCOUVER, BC / ACCESSWIRE / May 11, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company") is pleased to announce it has now signed and launched a new collaborative research project agreement with the University of British Columbia ("UBC") that enables the second stage of its cell marker research.
Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration TechnologiesVANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting and/or allowance of seven patent applications since December 2020.
Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in JapanVANCOUVER, BC / ACCESSWIRE / May 3, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Tsukasa Kumai, one of Japan's leading sports medicine clinicians, has agreed to be RepliCel's clinical advisor for the development and commercialization of its tendon regeneration product (RCT-01) in Japan.